Evolocumab 140 MG/ML + Standard of care (SOC)
ApprovedActive 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
STEMI - ST Elevation Myocardial Infarction
Conditions
STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
Trial Timeline
Sep 29, 2021 → May 22, 2028
NCT ID
NCT04951856About Evolocumab 140 MG/ML + Standard of care (SOC)
Evolocumab 140 MG/ML + Standard of care (SOC) is a approved stage product being developed by Amgen for STEMI - ST Elevation Myocardial Infarction. The current trial status is active. This product is registered under clinical trial identifier NCT04951856. Target conditions include STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04951856 | Approved | Active |
Competing Products
20 competing products in STEMI - ST Elevation Myocardial Infarction